88 related articles for article (PubMed ID: 17101096)
1. [mTOR inhibitors: pleiotropic antiproliferative drugs].
Pallet N; Beaune P; Thervet E; Legendre C; Anglicheau D
Med Sci (Paris); 2006 Nov; 22(11):947-52. PubMed ID: 17101096
[TBL] [Abstract][Full Text] [Related]
2. [Rapamycine and mTOR inhibitors: from bench to bedside].
Pallet N; Beaune P; Legendre C; Anglicheau D
Ann Biol Clin (Paris); 2006; 64(2):107-15. PubMed ID: 16556521
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
4. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
[TBL] [Abstract][Full Text] [Related]
5. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
6. mTOR-what does it do?
Hall MN
Transplant Proc; 2008 Dec; 40(10 Suppl):S5-8. PubMed ID: 19100909
[TBL] [Abstract][Full Text] [Related]
7. [mTOR, the mammalian target of rapamycin].
Julien LA; Roux PP
Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
[TBL] [Abstract][Full Text] [Related]
8. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
9. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors in hematologic malignancies.
Dancey JE
Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
14. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
[TBL] [Abstract][Full Text] [Related]
15. The mammalian target of rapamycin pathway and its role in molecular nutrition regulation.
Lian J; Yan XH; Peng J; Jiang SW
Mol Nutr Food Res; 2008 Apr; 52(4):393-9. PubMed ID: 18306429
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
17. [Antitumoral effect of proliferation signal inhibitors].
Dumortier J
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
[TBL] [Abstract][Full Text] [Related]
18. The role of the mammalian target of rapamycin (mTOR) in renal disease.
Lieberthal W; Levine JS
J Am Soc Nephrol; 2009 Dec; 20(12):2493-502. PubMed ID: 19875810
[TBL] [Abstract][Full Text] [Related]
19. Monitoring mammalian target of rapamycin (mTOR) activity.
Ikenoue T; Hong S; Inoki K
Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
[TBL] [Abstract][Full Text] [Related]
20. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Fingar DC; Blenis J
Oncogene; 2004 Apr; 23(18):3151-71. PubMed ID: 15094765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
